Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05980728

Connective Tissue Disease Patients With Pulmonary Hypertension

Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Definite diagnosis of CTD included Systemic lupus erythematosus(SLE) diagnosed according to the 2019 The European Alliance of Associations for Rheumatology(EULAR) criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
  • PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)>20 Millimeters of mercury(mmHg), Pulmonary Artery Wedge Pressure(PAWP)≤15mmHg, Pulmonary Vascular Resistance(PVR)>2 Wood

Exclusion criteria

  • significant interstitial lung disease or chronic obstructive pulmonary disease;
  • left heart disease or congenital heart disease associated with pulmonary hypertension;
  • chronic thromboembolic pulmonary hypertension;
  • portal hypertension;
  • drug or toxin exposure;
  • HIV infection;
  • any other diseases known to be associated with PAH;
  • age<18 years.

Treatment and study plan

No intervention

Other

No Intervention

Primary outcomes

  1. Death

    Time frame: 30 years

    number of participants with All cause death

Secondary outcomes

  1. Clinical worsening

    Time frame: 30 years

    number of participants with Hospitalization for worsening pulmonary arterial hypertension(PAH),lung or heart/lung transplant) or unsatisfactory long-term clinical response (the 6-minute walk distance decreased > 15% from baseline and World Health Organization(WHO) functional class III/IV symptoms assessed at two clinic visits separated by > 6 months after sufficient PAH targeted drug treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Qiang Wang, MD

CONTACT

[email protected]

+862568307588

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Registry information

Official study title

The Prognostic Value of Biomarker in Connective Tissue Disease Patients With Pulmonary Hypertension

Important dates

Study start
2023
Primary completion
2027
Study completion
2030
First posted
Aug 8, 2023
Registry last updated
Oct 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.